In this week's EuroBiotech Report, Malin pulled in a blockbuster €330 million IPO, putting it among the biggest ever European biotech listings. Malin is targeting pre-IPO biotechs, a group that will find it easier to access public markets if a European equivalent of the JOBS Act, the U.S. legislative rethink that opened the current biotech IPO window, is passed. And more.
Genfit's in-development drug for a pervasive liver disease failed to beat placebo in a midstage trial, but the company, undaunted, is setting sights on late-stage studies with eyes on what could be a blockbuster market.
Gastro drug developer Synergy Pharmaceuticals is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals.
San Diego's Conatus Pharmaceuticals said its in-development liver disease drug came through in a Phase II trial, results the company believes create a path to late-stage development.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the results of an informal survey in which readers weighed in on whether the unprecedented bull market for biotech is sustainable or a bubble ready to pop. Then, Carly Helfand discusses #FierceMadness, a single-elimination tournament of drug names going on over at FiercePharmaMarketing.
Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.
A consortium of financial trade groups has begun lobbying the European Commission to implement the sort of changes that triggered the U.S. biotech IPO boom. The European IPO Task Force specifically wants politicians to slash the regulatory and administrative cost of going public by up to 50%, a move that would make it financially feasible for more small companies to float.
Amgen's deCODE Genetics has published a series of papers that hint at how the the Big Biotech could begin to recoup the $415 million it paid for the population-scale sequencing pioneer. For Amgen, the meat of the project lies in the discovery of 8,000 human knockouts, people who lack a working version of one of 1,171 genes.
Cellectis, a French company with a proprietary spin on one of biotech's hottest fields, made an up-sized debut on Wall Street, grossing more than $228 million.
Novartis became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own.
Maryland's Emergent BioSolutions won FDA approval for an injected treatment for anthrax infection, padding the company's stable of biodefense products.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
GlaxoSmithKline is looking for some new partners in academia, launching a contest for would-be collaborators with early-stage projects that could translate into marketable medicines.
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects when they start to look futile, a philosophy that trickles down to Novartis' lab work.
Cellectis has tossed aside its earlier IPO targets as strong demand and a surge in its European stock price have encouraged it to pitch for a bumper listing. The French CAR-T player is now aiming to raise $197 million before the overallotment, 70% more than it was targeting when it first filed its papers last month.
While biotech companies herald early-stage advances in Alzheimer's disease R&D, neuroscientists remain sharply divided as to just which protein--beta amyloid or tau--most contributes to the disorder's memory-destroying effect, and a new study has rekindled the debate.
Cambridge, MA's Blueprint Medicines is lining up to raise $100 million in an IPO to advance a stable of personalized cancer treatments and build out its pipeline.
Joint Polish Investment Fund Management is claiming a first. The Warsaw, Poland-based group has reportedly become the country's first institutional venture capital fund dedicated to life sciences after it held the initial closing of its $42 million (€38 million) investment vehicle.
Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.